The trajectory of companies tied to Sildenafil's legacy presents a challenging investment scenario . While the initial boom generated substantial gains, generic alternatives have significantly diminished sales . Investing in associated pharmaceutical firms now requires a discerning assessment of proprietary protection , evolving healthcare changes,